Skip to main content

Table 1 Comparison of anti-PD-1 adjuvant trials

From: Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)

Data comparison in adjuvant melanoma trials
Patient population CM238 [60] COMBI-AD [61] KN054 [4]
Completely resected stage IIIB/C or IV melanoma Completely resected, BRAFV600E/K-positive stage IIIA/B/C melanoma Completely resected stage IIIA/B/C melanoma
Treatment Nivo Lpi Dab/Tram Placebo Pembro Placebo
N 453 453 438 432 514 505
RFS HR 0.65 (97.56% CI 0.51–0.83), P < 0.0001 0.47 (95% CI 0.39–0.58), P < 0.001 0.57 (98.4% CI 0.43–0.74), P < 0.001
1-year RFS rate (%) 71 61 88 56 75 61
18-months RFS rate (%) 66 53 N/A N/A 71 53
3-years OS rate (%) N/A N/A 86 77 N/A N/A
Grade 3–5 TRAEs (%) 14 46 31 5 15 3
DC rate due to AEs (%) 10 43 26 3 14 2
  1. In italic values for 1-y RFS Rate (%), patients treated with nivolumab Grade 3-5 TREs (%) and patients treated with nivolumab DC Rate due to AEs (%)
  2. Comparison of three trials showing a consistent beneficial effect on RFS with adjuvant PD-1 inhibitor therapy, although OS data is largely still awaited